

# Multiple Sclerosis in Latin America

Teresa Corona<sup>a</sup> Gustavo C. Román<sup>b</sup>

<sup>a</sup>National Institute of Neurology and Neurosurgery, Mexico City, Mexico; <sup>b</sup>University of Texas Health Science Center at San Antonio, San Antonio, Tex., USA

## Key Words

Multiple sclerosis, geographic distribution · Latin America

## Introduction

The epidemiology of multiple sclerosis (MS) has been thoroughly studied in developed countries, particularly in areas traditionally known for their high prevalence. However, there is a dearth of epidemiological information on MS from large areas of the world. It is generally accepted that MS incidence and prevalence are higher in latitudes north and south of the Equator with prevalences ranging from 80 to 300/100,000. In contrast, its prevalence in Africa, Asia and South America has been estimated around 5/100,000 [1, 2]. However, lack of adjustment of crude incidence and prevalence rates to a common standard population creates problems in the comparison and interpretation of geographic data [3]. Nonetheless, recent studies indicate an increasing risk of developing MS over time in areas such as Sardinia [4], Norway [5], and Sweden [6], as well as in countries previously considered to have low MS prevalence such as Mexico [7].

## MS in Latin America

During the last decade, there has been a surge of research interest on the epidemiology of MS in Latin America. Despite some methodological shortcomings, recently

published epidemiological studies begin to provide a reasonable estimate of the frequency and characteristics of MS in Latin America.

In Mexico, hospital-based and population-based studies indicate an increase in the incidence and prevalence of MS. In 1970, Alter and Olivares [8] reported a relatively low prevalence of 1.6/100,000. This study was not confirmed by community-based data. More recent studies based on referrals to a tertiary neurological center demonstrate an important increase in MS incidence [9–11]. A study in northern Mexico (25° north) found a prevalence of 13/100,000 inhabitants [9]. However, this study included only patients with social security benefits, representing 51% of the population. Other studies performed in central areas of the country have registered lower prevalences of about 5/100,000 at latitudes 16–20° north [10]. Clearly, MS has become one of the main causes of neurological consultation in Mexico. For instance, optic neuritis represents 12% of the patients referred to a specialized neuro-ophthalmology clinic [12]; about 40% of them are eventually diagnosed as having MS [12, 13]. Potential risk factors responsible for the increase in MS in Mexico include a decrease in breastfeeding for large segments of the society and an increased incidence of varicella and childhood eczema [14]. Research conducted at the National Institute of Neurology and Neurosurgery of Mexico has demonstrated activation of varicella-zoster virus during MS relapses [15], suggesting that this herpes virus could be an etiological agent of MS.

In 1999, the Latin American Committee for Treatment and Research in MS (LACTRIMS) was formally organized generating renewed interest in numerous coun-

tries [16, 17]. In Argentina, Cristiano et al. [18], using a capture-recapture method, reported a prevalence of MS of 12/100,000, indicating a low-intermediate risk. However, prevalences as high as 88/100,000 have been reported [19]. Studies from Brazil show variable prevalences within the country [20, 21], perhaps due to their ethnic heterogeneity. In Sao Paulo (23–24° south), Callegaro et al. [22] found a prevalence of 15/100,000. In Uruguay, Ketzoian et al. [23] found in a capture-recapture study a prevalence of 20.9/100,000. In Colombia, MS prevalence shows geographic variations ranging from 1.48 to 4.98/100,000 [24]. Genetic studies in Medellin demonstrated in this population that HLA DQAI polymorphisms at chromosome 6p21.3–21.4 were associated with a high or low predisposition to suffer from MS [25, 26]. Of interest, MS in this genetically homogeneous population presented clinically with a preponderance of optic neuritis and motor symptoms in the absence of cerebellar manifestations [27]. This pattern is significantly different from that observed at onset in temperate regions. In

Chile, MS corresponds to 3.4% of hospitalized patients in the city of Santiago [28]; a recent study reported a prevalence of 11.7/100,000 [29].

In the Caribbean, a few studies have reported case series from Puerto Rico [30] and Cuba [31], but prevalence data appear unreliable. The presence of epidemic optic myeloneuropathy in Cuba [32], and tropical spastic paraparesis from HTLV-I infections of the nervous system [33] in the Caribbean, constitutes complicating factors for prevalence studies of MS in this region.

In conclusion, there is growing epidemiological evidence indicating an increased prevalence of MS in areas previously considered as low risk in Latin America. It should be mentioned that the social and economic conditions in Latin America often exclude patients with bona fide MS from adequate treatment. It is hoped that future studies on the natural history, genetics and environmental factors at play in these populations will contribute to elucidate the etiology and pathogenesis of MS.

## References

- Poser CM: An atlas of multiple sclerosis; in Poser CM (ed): Multiple Sclerosis. New York, Parthenon Publishing Group, 1998.
- Kurtzke JF: Epidemiology and etiology of multiple sclerosis. *Phys Med Rehabil Clin North Am* 2005;16:327–349.
- Zivadnov R, Iona L, Monti-Bragadin L, Bosco A, Jurjevic A, Taus C, Cazzato G, Zorzon M: The use of standardized incidence and prevalence rates in epidemiological studies on multiple sclerosis: a meta-analysis study. *Neuroepidemiology* 2003;22:65–74.
- Pugliatti M, Riise T, Sotgiu MA, Sotgiu S, Satta WM, Mannu L, Sanna G, Rosati G: Increasing incidence of multiple sclerosis in the province of Sassari, northern Sardinia. *Neuroepidemiology* 2005;25:129–134.
- Dahl OP, Aarseth JH, Myhr KM, Nyland H, Midgard R: Multiple sclerosis in Nord-Trøndelag County, Norway: a prevalence and incidence study. *Acta Neurol Scand* 2004;109:378–384.
- Sundström P, Nyström L, Forsgren L: Incidence (1988–1997) and prevalence (1997) of multiple sclerosis in Vasterbotten County in northern Sweden. *J Neurol Neurosurg Psychiatry* 2003;74:29–32.
- González O, Sotelo J: Is the frequency of multiple sclerosis increasing in México? *J Neurol Neurosurg Psychiatry* 1995;59:528–530.
- Alter M, Olivares O: Multiple sclerosis in México. *Arch Neurol* 1970;23: 451–459.
- Velázquez M, Macias MA, Rivera OV, Lozano Z: Grupo Mexicano de estudio de la esclerosis múltiple. *Rev Neurol* 2003;36:1019–1022.
- Corona T, Rodríguez LJ, Otero E, Stopp L: Multiple sclerosis in México: hospital cases at the National Institute of Neurology and Neurosurgery. *Neurología* 1996;11:170–173.
- Aguilar F, Estañol B, Del Angel A, Cabañas A, López G, Benítez L: Esclerosis múltiple: estudio clínico, paraclínico y manejo de 24 casos. *Rev Invest Clin* 1985;37:231–235.
- Corona T, Ruiz JL, Arriada N: Optic neuritis progressing to multiple sclerosis. *Acta Neurol Scand* 1997;95: 85–89.
- Lazo M, Corona T: Neuritis óptica: seguimiento a largo plazo en población mexicana. *Rev Neurol* 2002;35:1190.
- Tartas R, Ordoñez G, Rios C, Sotelo J: Varicella, ephemeral breastfeeding and eczema as risk factors for multiple sclerosis in Mexicans. *Acta Neurol Scand* 2002;105:88–94.
- Ordoñez G, Pineda B, Garcia-Navarrete R, Sotelo J: Brief presence of varicella-zoster viral DNA in mononuclear cells during relapses of multiple sclerosis. *Arch Neurol* 2004;61:529–532.
- Rivera VM, Cabrera JA: Avance de la esclerosis múltiple en Latinoamérica. *Médico Interam* 2000;19:458–465.
- Rivera VM: Simposio de esclerosis múltiple en Houston: introducción. *Rev Neurol* 2003;31: 469.
- Cristiano E, Patrucco L, Garcea O, Carra A, Cáceres F, Kremenchutsky M, et al: Prevalence of multiple sclerosis (MS) in Argentina using the capture-recapture method. *Neurology* 1999;2(suppl):A438.
- Piedrabuena R, Giobellina R, Alvarez D, Abatedaga V: High prevalence of multiple sclerosis in the city of Oliva, Cordoba, Argentina. *Arq Neuropsiquiatr* 2004;62:13.
- Papais-Alvarenga R, Alves S, Miranda C, Tilbery C, Poser CM, Alvarenga H, et al: Characteristics of multiple sclerosis in Brazil: multicentric study in a prevalence cohort – South Atlantic project phase I. *J Neurol Sci* 1997; 150:S229.
- Gama P, Trigo L, Andrade R, Sala C: On behalf of the Brazilian Committee for Treatment and Research in Multiple Sclerosis (BCTRIMS): epidemiological study of multiple sclerosis in the city of Sorocaba, Brazil. *Arq Neuropsiquiatr* 2004;62:13.
- Callegaro D, Godbaum M, Morais L, Tilbery CP, Moreira MA, Gabbai AA, Scaff M: The prevalence of multiple sclerosis in the city of Sao Paulo, Brazil. *Acta Neurol Scand* 2001; 104:2208–2137.
- Ketzoian C, Oeninger C, Alcántaran J, et al: Estudio de la prevalencia de la esclerosis múltiple en Uruguay. *Acta Neurol Col* 1999;15:6.

- 24 Sánchez JL, Aguirre C, Arcos OM, Jiménez I, Jiménez M, León F, et. al: Prevalencia de la esclerosis múltiple en Colombia. *Rev Neurol* 2000;31:1101-1103.
- 25 Palacio LG, Rivera D, Builes JJ, Jiménez ME, Salgar M, Anaya JM, Jiménez I, Camargo M, Arcos-Burgos M, Sánchez JL: Multiple sclerosis in the tropics: genetic association to STR's loci spanning the HLA and TNF. *Mult Scler* 2002;8:249-255.
- 26 Arcos-Burgos M, Palacio G, Sánchez JL, Londoño AC, Uribe CS, Jiménez M, Villa A, Anaya JM, Bravo ML, Jaramillo N, Espinal C, Builes JJ, Moreno M, Jiménez I: Multiple sclerosis: association to HLA DQ $\alpha$  in a tropical population. *Exp Clin Immunogenet* 1999;16:131-138.
- 27 Sánchez JL, Palacio LG, Uribe CS, Londoño AC, Villa A, Jiménez M, Anaya JM, Jiménez I, Camargo M, Arcos-Burgos M: Clinical features of multiple sclerosis in a genetically homogeneous tropical population. *Mult Scler* 2001;7:227-229.
- 28 Alvarez G, Castillo J, Cárdenas M, Fauré E, Ruíz F, Lavados J: Multiple sclerosis in Chile. *Acta Neurol Scand* 1992;85:1-4.
- 29 Barahona J, Montero A, Flores A: Multiple sclerosis in Chile. *Arq Neuropsiquiatr* 2004;62:11.
- 30 Sánchez LP, Fiol M, Cedó P: Multiple sclerosis in Puerto Rico (experience at the university hospital): review of a series of cases. *Bol Asoc Med P Rico* 1972;64:176-178.
- 31 Cabrera-Gómez JA, López O: Morbilidad por enfermedades neurológicas en el Servicio de Neurología: estudio de un quinquenio. *Rev Cubana Med* 1990;29:161-172.
- 32 Román GC: An epidemic in Cuba of optic neuropathy, sensorineural deafness, peripheral sensory neuropathy and dorsolateral myeloneuropathy. *J Neurol Sci* 1994;127:11-28.
- 33 Román GC, Vernant J-C, Osame M (eds): HTLV-I and the Nervous System. New York, Liss, 1989.